Skip to main content
. 2012 Jul 30;7(7):e40362. doi: 10.1371/journal.pone.0040362

Table 1. Baseline demographic, clinical and immunological characteristics of RA patients included in the study.

RA patients
N 138
Gender: Female, n. (%) 114 (82.6)
Age (years) 61.3±11.5
Disease duration (years) 13.0±10.6
Anti-TNF naïve, n (%) 35 (25.4)
Previous anti-TNF agents used
N = 1, n (%) 43 (41.7)
N = 2, n (%) 48 (46.6)
N = 3, n (%) 12 (11.7)
Current DMARDs therapy, n (%) 122 (88.4)
Current steroid therapy, n (%) 110 (80.3)
Tender joint count (n) 18.8±12.6
Swollen joint count (n) 10.9±7.6
CRP (mg/L) 21.6±22.6
ESR (mm/1st hour) 48.5±25.4
DAS 4.6±1.2
HAQ 1.66±0.74
Anti-CCP IgG (U/ml) 190.2±127.0 (151.0)*
Anti-CCP IgG ≥7.0 U/ml, n (%) 116/137 (84.7)
Anti-CCP IgM (U/ml) 371.1±281.1 (303.0)*
Anti-CCP IgM ≥100 U/ml, n (%) 33/137 (24.1)
Anti-CCP IgA (U/ml) 20.4±24.1 (7.5)*
Anti-CCP IgA ≥2.2 U/ml, n (%) 66/137 (48.2)
RF-IgG (U/ml) 174.0±216.7 (102.3)*
RF-IgG ≥20U/ml, n (%) 111/137 (81.0)
RF-IgM (U/ml) 156.3±158.3 (89.4)*
RF-IgM ≥20U/ml, n (%) 89 (64.5)
RF-IgA (U/ml) 159.5±176.0 (90.1)*
RF-IgA ≥20U/ml, n (%) 74 (53.6)
Anti-MCV (U/ml) 447.7±465.7 (216.3)*
Anti-MCV ≥20U/ml, n (%) 123 (89.1)

Values are mean ± sd unless otherwise indicated. *values are reported as mean ± sd (median).

RA = rheumatoid arthritis; TNF = tumor necrosis factor; DMARDs = disease modified anti-rheumatic drugs; CRP = C-reactive protein; ESR =  erythrocyte sedimentation rate; DAS =  disease activity score; HAQ = Health Assessment Questionnaire; CCP = cyclic citrullinated protein; RF =  rheumatoid factor; MCV =  modified citrullinated vimentin.